Pediatric Promise: China Bets On Better Medicines Amid Three Child Policy Roll-Out
But Industry Incentives Still Limited
As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.
You may also be interested in...
Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.
COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.